NCT04175522View on ClinicalTrials.gov

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

June 11, 2020

Study Completion Date

June 11, 2020

Conditions
Autoimmune Encephalitis
Interventions
DRUG

Immunoglobulin G

IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY